Invention Grant
US07863030B2 Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
有权
修饰的细胞色素P450的区域和对映选择性烷烃羟基化
- Patent Title: Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
- Patent Title (中): 修饰的细胞色素P450的区域和对映选择性烷烃羟基化
-
Application No.: US12424454Application Date: 2009-04-15
-
Publication No.: US07863030B2Publication Date: 2011-01-04
- Inventor: Frances H Arnold , Matthew W Peters , Peter Meinhold
- Applicant: Frances H Arnold , Matthew W Peters , Peter Meinhold
- Applicant Address: US CA Pasadena
- Assignee: The California Institute of Technology
- Current Assignee: The California Institute of Technology
- Current Assignee Address: US CA Pasadena
- Agency: Gavrilovich Dodd & Lindsey LLP
- Agent Joseph R. Baker, Jr.
- Main IPC: C12N9/02
- IPC: C12N9/02 ; C12N15/00 ; C12N1/20 ; C12P7/00 ; C12P21/04 ; C07H21/04 ; C12Q1/68 ; C12Q1/00 ; C12Q1/26

Abstract:
Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
Public/Granted literature
- US20090298148A1 REGIO- AND ENANTIOSELECTIVE ALKANE HYDROXYLATION WITH MODIFIED CYTOCHROME P450 Public/Granted day:2009-12-03
Information query